In conclusion, GVS-12 suppressed the development of NASH by down-regulating the mRNA expression of IL-1β, IL-6 and TNF-α via PPARγ/STAT3 signaling pathways. The gene discussed is IL6; the disease is metabolic dysfunction-associated steatohepatitis.